DYN
insider transactionsDyne Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
+2.8K
6.5K buy · 3.7K sell
Net value · 30d
$45.9K
$114.0K in · $68.1K out
Sentiment · 30d
Net buying
63% buying · 37% selling
Open-market trades · 30d
6
6.5K buy · 3.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Commercial Officer · 10b5-1
$2.7K
145 sh · $18.33
Own -0%
-
Sell·S
Chief Medical Officer · 10b5-1
$16.3K
887 sh · $18.33
Own -1%
-
Sell·S
John Cox KEY
CEO & President · 10b5-1
$49.2K
2.7K sh · $18.33
Own -1%
-
Buy·P
Director
$33.9K
2.0K sh · $16.94
Own +9%
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Grant·A
Director
$0
35.2K sh
Own New
-
Buy·P
Director
$43.7K
2.5K sh · $17.48
Own +12%
-
Buy·P
Director
$36.4K
2.0K sh · $18.21
Own +11%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Johanna Friedl-Naderer 10b5-1 | Sell S | 145 | $2.7K |
| Jun 16, 2026 | Douglas Kerr 10b5-1 | Sell S | 887 | $16.3K |
| Jun 16, 2026 | John Cox KEY 10b5-1 | Sell S | 2.7K | $49.2K |
| Jun 8, 2026 | Brian S Posner | Buy P | 2.0K | $33.9K |
| Jun 5, 2026 | Edward Hurwitz | Grant A | 35.2K | $0 |
| Jun 5, 2026 | David Charles Lubner | Grant A | 35.2K | $0 |
| Jun 5, 2026 | Jason P Rhodes | Grant A | 35.2K | $0 |
| Jun 5, 2026 | Dirk Kersten | Grant A | 35.2K | $0 |
| Jun 5, 2026 | Carlo Incerti | Grant A | 35.2K | $0 |
| Jun 5, 2026 | Catherine Stehman-Breen | Grant A | 35.2K | $0 |
| Jun 5, 2026 | Brian S Posner | Grant A | 35.2K | $0 |
| Jun 3, 2026 | Brian S Posner | Buy P | 2.5K | $43.7K |
| May 26, 2026 | Brian S Posner | Buy P | 2.0K | $36.4K |
About DYN insider trading
This page tracks insider transactions for Dyne Therapeutics, Inc. (DYN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.